➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Express Scripts
Mallinckrodt
Merck
Baxter

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Patent: 9,982,032

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,982,032
Title:Stable liquid formulation of fusion protein with IgG Fc domain
Abstract: A stable liquid formulation includes a fusion protein having an Fc domain of a human immunoglobulin G (IgG), in particular, a protein in which an Fc domain of a human immunoglobulin G (IgG) and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor are fused (e.g., aflibercept)). A composition for stabilizing a protein and a method for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused are disclosed. The present invention improves therapeutic effects on various ophthalmic diseases (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) caused by abnormal angiogenesis, while pursuing stabilization of bioactivity through a stable liquid formulation suitable for intravitreal injection of an anti-VEGF-Fc fusion protein including aflibercept.
Inventor(s): Park; Soon Jae (Daejeon, KR), Chung; Hye-Shin (Daejeon, KR), Kim; Jin Hwan (Daejeon, KR), Kim; Yong Mo (Daejeon, KR), Kim; Jun Young (Daejeon, KR)
Assignee: ALTEOGEN, INC. (Daejeon, KR)
Application Number:15/190,378
Patent Claims:see list of patent claims

Details for Patent 9,982,032

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Octapharma Usa Inc CUTAQUIG immunoglobulin g SOLUTION 125668 1 2019-05-03   Start Trial ALTEOGEN, INC. (Daejeon, KR) 2035-06-23 search
Adma Biologics, Inc. ASCENIV human immunoglobulin g LIQUID 125590 1 2019-04-01   Start Trial ALTEOGEN, INC. (Daejeon, KR) 2035-06-23 search
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial ALTEOGEN, INC. (Daejeon, KR) 2035-06-23 RX search
Csl Behring Ag HIZENTRA human immunoglobulin g LIQUID 125350 1 2020-01-01   Start Trial ALTEOGEN, INC. (Daejeon, KR) 2035-06-23 search
Bio Products Laboratory Limited GAMMAPLEX human immunoglobulin g SOLUTION 125329 1 2017-04-07   Start Trial ALTEOGEN, INC. (Daejeon, KR) 2035-06-23 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Harvard Business School
Colorcon
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.